TIPE2 deficiency accelerates neointima formation by downregulating smooth muscle cell differentiation.

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Atherosclerosis Research

Background:

• Vascular smooth muscle cell (VSMC) phenotypic switching is crucial in atherosclerosis development.
• Mechanisms governing VSMC phenotypic switching remain incompletely understood.

Purpose of the Study:

• To investigate the role of TIPE2 (tumor necrosis factor α-induced protein 8-like 2) in regulating VSMC phenotype.
• To determine TIPE2's function in the context of oxidized low-density lipoprotein (ox-LDL) stimulation and atherosclerosis.

Main Methods:

• Analysis of VSMC phenotype markers (SMαA, SM-MHC, calponin) in TIPE2-deficient cells.
• Assessment of VSMC proliferation, migration, and synthetic capacity.
• Evaluation of cell cycle progression (G1/S transition) and kinase signaling pathways (p38, ERK1/2).
• In vivo studies using TIPE2-deficient mice to assess neointima formation in carotid arteries.

Main Results:

• TIPE2 deficiency in VSMCs treated with ox-LDL led to decreased contractile proteins and increased proliferation, migration, and cytokine production.
• TIPE2 inhibited VSMC proliferation by blocking G1/S phase transition, dependent on p38 and ERK1/2 signaling.
• TIPE2-deficient mice exhibited accelerated neointima formation in carotid arteries.

Conclusions:

• TIPE2 plays a significant atheroprotective role by modulating VSMC phenotypic switching.
• TIPE2 is a potential therapeutic target for inhibiting atherosclerosis progression.